カテゴリ： 世界, 医療/バイオ, Market Monitor Global

CD161抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル

■ 英語タイトル：CD161 Antibody Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC12288）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC12288
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医療
■ ページ数：104
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[CD161抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界のCD161抗体市場規模と予測を収録しています。・世界のCD161抗体市場：売上、2018年-2023年、2024年-2029年
・世界のCD161抗体市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のCD161抗体市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「モノクローナル」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

CD161抗体のグローバル主要企業は、BD Biosciences、 GeneTex、 RayBiotech、 LifeSpan BioSciences、 BioLegend、 Abeomics、 Bioss、 Novus Biologicals、 Tonbo Biosciences、 Bio-Rad、 Cell Sciences、 Miltenyi Biotec、 R&D Systems、 BMA Biomedicals、 AAT Bioquest、 Biobyt、 Jingjie PTM BioLabなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、CD161抗体のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のCD161抗体市場：タイプ別、2018年-2023年、2024年-2029年
世界のCD161抗体市場：タイプ別市場シェア、2022年
・モノクローナル、ポリクローナル

世界のCD161抗体市場：用途別、2018年-2023年、2024年-2029年
世界のCD161抗体市場：用途別市場シェア、2022年
・免疫化学（IHC）、免疫蛍光（IF）、免疫沈降（IP）、ウェスタンブロット（WB）、ELISA、その他

世界のCD161抗体市場：地域・国別、2018年-2023年、2024年-2029年
世界のCD161抗体市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるCD161抗体のグローバル売上、2018年-2023年
・主要企業におけるCD161抗体のグローバル売上シェア、2022年
・主要企業におけるCD161抗体のグローバル販売量、2018年-2023年
・主要企業におけるCD161抗体のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
BD Biosciences、 GeneTex、 RayBiotech、 LifeSpan BioSciences、 BioLegend、 Abeomics、 Bioss、 Novus Biologicals、 Tonbo Biosciences、 Bio-Rad、 Cell Sciences、 Miltenyi Biotec、 R&D Systems、 BMA Biomedicals、 AAT Bioquest、 Biobyt、 Jingjie PTM BioLab

*************************************************************

・調査・分析レポートの概要
CD161抗体市場の定義
市場セグメント
世界のCD161抗体市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のCD161抗体市場規模
世界のCD161抗体市場規模：2022年 VS 2029年
世界のCD161抗体市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのCD161抗体の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のCD161抗体製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：モノクローナル、ポリクローナル
CD161抗体のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：免疫化学（IHC）、免疫蛍光（IF）、免疫沈降（IP）、ウェスタンブロット（WB）、ELISA、その他
CD161抗体の用途別グローバル売上・予測

・地域別市場分析
地域別CD161抗体市場規模 2022年と2029年
地域別CD161抗体売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
BD Biosciences、 GeneTex、 RayBiotech、 LifeSpan BioSciences、 BioLegend、 Abeomics、 Bioss、 Novus Biologicals、 Tonbo Biosciences、 Bio-Rad、 Cell Sciences、 Miltenyi Biotec、 R&D Systems、 BMA Biomedicals、 AAT Bioquest、 Biobyt、 Jingjie PTM BioLab
...

This research report provides a comprehensive analysis of the CD161 Antibody market, focusing on the current trends, market dynamics, and future prospects. The report explores the global CD161 Antibody market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of CD161 Antibody, challenges faced by the industry, and potential opportunities for market players.
The global CD161 Antibody market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The CD161 Antibody market presents opportunities for various stakeholders, including Immunochemistry (IHC), Immunofluorescence (IF). Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in CD161 Antibody market. Additionally, the growing consumer demand present avenues for market expansion.
The global CD161 Antibody market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the CD161 Antibody market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the CD161 Antibody market.
Market Overview: The report provides a comprehensive overview of the CD161 Antibody market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Monoclonal, Polyclonal), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the CD161 Antibody market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the CD161 Antibody market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the CD161 Antibody market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the CD161 Antibody market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the CD161 Antibody market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the CD161 Antibody market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for CD161 Antibody, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the CD161 Antibody market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
CD161 Antibody market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Monoclonal
Polyclonal
Market segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
Global CD161 Antibody Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
BD Biosciences
GeneTex
RayBiotech
LifeSpan BioSciences
BioLegend
Abeomics
Bioss
Novus Biologicals
Tonbo Biosciences
Bio-Rad
Cell Sciences
Miltenyi Biotec
R&D Systems
BMA Biomedicals
AAT Bioquest
Biobyt
Jingjie PTM BioLab
Outline of Major Chapters:
Chapter 1: Introduces the definition of CD161 Antibody, market overview.
Chapter 2: Global CD161 Antibody market size in revenue.
Chapter 3: Detailed analysis of CD161 Antibody company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CD161 Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 CD161 Antibody Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global CD161 Antibody Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global CD161 Antibody Overall Market Size
2.1 Global CD161 Antibody Market Size: 2022 VS 2029
2.2 Global CD161 Antibody Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top CD161 Antibody Players in Global Market
3.2 Top Global CD161 Antibody Companies Ranked by Revenue
3.3 Global CD161 Antibody Revenue by Companies
3.4 Top 3 and Top 5 CD161 Antibody Companies in Global Market, by Revenue in 2022
3.5 Global Companies CD161 Antibody Product Type
3.6 Tier 1, Tier 2 and Tier 3 CD161 Antibody Players in Global Market
3.6.1 List of Global Tier 1 CD161 Antibody Companies
3.6.2 List of Global Tier 2 and Tier 3 CD161 Antibody Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global CD161 Antibody Market Size Markets, 2022 & 2029
4.1.2 Monoclonal
4.1.3 Polyclonal
4.2 By Type – Global CD161 Antibody Revenue & Forecasts
4.2.1 By Type – Global CD161 Antibody Revenue, 2018-2023
4.2.2 By Type – Global CD161 Antibody Revenue, 2024-2029
4.2.3 By Type – Global CD161 Antibody Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global CD161 Antibody Market Size, 2022 & 2029
5.1.2 Immunochemistry (IHC)
5.1.3 Immunofluorescence (IF)
5.1.4 Immunoprecipitation (IP)
5.1.5 Western Blot (WB)
5.1.6 ELISA
5.1.7 Others
5.2 By Application – Global CD161 Antibody Revenue & Forecasts
5.2.1 By Application – Global CD161 Antibody Revenue, 2018-2023
5.2.2 By Application – Global CD161 Antibody Revenue, 2024-2029
5.2.3 By Application – Global CD161 Antibody Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global CD161 Antibody Market Size, 2022 & 2029
6.2 By Region – Global CD161 Antibody Revenue & Forecasts
6.2.1 By Region – Global CD161 Antibody Revenue, 2018-2023
6.2.2 By Region – Global CD161 Antibody Revenue, 2024-2029
6.2.3 By Region – Global CD161 Antibody Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America CD161 Antibody Revenue, 2018-2029
6.3.2 US CD161 Antibody Market Size, 2018-2029
6.3.3 Canada CD161 Antibody Market Size, 2018-2029
6.3.4 Mexico CD161 Antibody Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe CD161 Antibody Revenue, 2018-2029
6.4.2 Germany CD161 Antibody Market Size, 2018-2029
6.4.3 France CD161 Antibody Market Size, 2018-2029
6.4.4 U.K. CD161 Antibody Market Size, 2018-2029
6.4.5 Italy CD161 Antibody Market Size, 2018-2029
6.4.6 Russia CD161 Antibody Market Size, 2018-2029
6.4.7 Nordic Countries CD161 Antibody Market Size, 2018-2029
6.4.8 Benelux CD161 Antibody Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia CD161 Antibody Revenue, 2018-2029
6.5.2 China CD161 Antibody Market Size, 2018-2029
6.5.3 Japan CD161 Antibody Market Size, 2018-2029
6.5.4 South Korea CD161 Antibody Market Size, 2018-2029
6.5.5 Southeast Asia CD161 Antibody Market Size, 2018-2029
6.5.6 India CD161 Antibody Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America CD161 Antibody Revenue, 2018-2029
6.6.2 Brazil CD161 Antibody Market Size, 2018-2029
6.6.3 Argentina CD161 Antibody Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa CD161 Antibody Revenue, 2018-2029
6.7.2 Turkey CD161 Antibody Market Size, 2018-2029
6.7.3 Israel CD161 Antibody Market Size, 2018-2029
6.7.4 Saudi Arabia CD161 Antibody Market Size, 2018-2029
6.7.5 UAE CD161 Antibody Market Size, 2018-2029
7 CD161 Antibody Companies Profiles
7.1 BD Biosciences
7.1.1 BD Biosciences Company Summary
7.1.2 BD Biosciences Business Overview
7.1.3 BD Biosciences CD161 Antibody Major Product Offerings
7.1.4 BD Biosciences CD161 Antibody Revenue in Global Market (2018-2023)
7.1.5 BD Biosciences Key News & Latest Developments
7.2 GeneTex
7.2.1 GeneTex Company Summary
7.2.2 GeneTex Business Overview
7.2.3 GeneTex CD161 Antibody Major Product Offerings
7.2.4 GeneTex CD161 Antibody Revenue in Global Market (2018-2023)
7.2.5 GeneTex Key News & Latest Developments
7.3 RayBiotech
7.3.1 RayBiotech Company Summary
7.3.2 RayBiotech Business Overview
7.3.3 RayBiotech CD161 Antibody Major Product Offerings
7.3.4 RayBiotech CD161 Antibody Revenue in Global Market (2018-2023)
7.3.5 RayBiotech Key News & Latest Developments
7.4 LifeSpan BioSciences
7.4.1 LifeSpan BioSciences Company Summary
7.4.2 LifeSpan BioSciences Business Overview
7.4.3 LifeSpan BioSciences CD161 Antibody Major Product Offerings
7.4.4 LifeSpan BioSciences CD161 Antibody Revenue in Global Market (2018-2023)
7.4.5 LifeSpan BioSciences Key News & Latest Developments
7.5 BioLegend
7.5.1 BioLegend Company Summary
7.5.2 BioLegend Business Overview
7.5.3 BioLegend CD161 Antibody Major Product Offerings
7.5.4 BioLegend CD161 Antibody Revenue in Global Market (2018-2023)
7.5.5 BioLegend Key News & Latest Developments
7.6 Abeomics
7.6.1 Abeomics Company Summary
7.6.2 Abeomics Business Overview
7.6.3 Abeomics CD161 Antibody Major Product Offerings
7.6.4 Abeomics CD161 Antibody Revenue in Global Market (2018-2023)
7.6.5 Abeomics Key News & Latest Developments
7.7 Bioss
7.7.1 Bioss Company Summary
7.7.2 Bioss Business Overview
7.7.3 Bioss CD161 Antibody Major Product Offerings
7.7.4 Bioss CD161 Antibody Revenue in Global Market (2018-2023)
7.7.5 Bioss Key News & Latest Developments
7.8 Novus Biologicals
7.8.1 Novus Biologicals Company Summary
7.8.2 Novus Biologicals Business Overview
7.8.3 Novus Biologicals CD161 Antibody Major Product Offerings
7.8.4 Novus Biologicals CD161 Antibody Revenue in Global Market (2018-2023)
7.8.5 Novus Biologicals Key News & Latest Developments
7.9 Tonbo Biosciences
7.9.1 Tonbo Biosciences Company Summary
7.9.2 Tonbo Biosciences Business Overview
7.9.3 Tonbo Biosciences CD161 Antibody Major Product Offerings
7.9.4 Tonbo Biosciences CD161 Antibody Revenue in Global Market (2018-2023)
7.9.5 Tonbo Biosciences Key News & Latest Developments
7.10 Bio-Rad
7.10.1 Bio-Rad Company Summary
7.10.2 Bio-Rad Business Overview
7.10.3 Bio-Rad CD161 Antibody Major Product Offerings
7.10.4 Bio-Rad CD161 Antibody Revenue in Global Market (2018-2023)
7.10.5 Bio-Rad Key News & Latest Developments
7.11 Cell Sciences
7.11.1 Cell Sciences Company Summary
7.11.2 Cell Sciences Business Overview
7.11.3 Cell Sciences CD161 Antibody Major Product Offerings
7.11.4 Cell Sciences CD161 Antibody Revenue in Global Market (2018-2023)
7.11.5 Cell Sciences Key News & Latest Developments
7.12 Miltenyi Biotec
7.12.1 Miltenyi Biotec Company Summary
7.12.2 Miltenyi Biotec Business Overview
7.12.3 Miltenyi Biotec CD161 Antibody Major Product Offerings
7.12.4 Miltenyi Biotec CD161 Antibody Revenue in Global Market (2018-2023)
7.12.5 Miltenyi Biotec Key News & Latest Developments
7.13 R&D Systems
7.13.1 R&D Systems Company Summary
7.13.2 R&D Systems Business Overview
7.13.3 R&D Systems CD161 Antibody Major Product Offerings
7.13.4 R&D Systems CD161 Antibody Revenue in Global Market (2018-2023)
7.13.5 R&D Systems Key News & Latest Developments
7.14 BMA Biomedicals
7.14.1 BMA Biomedicals Company Summary
7.14.2 BMA Biomedicals Business Overview
7.14.3 BMA Biomedicals CD161 Antibody Major Product Offerings
7.14.4 BMA Biomedicals CD161 Antibody Revenue in Global Market (2018-2023)
7.14.5 BMA Biomedicals Key News & Latest Developments
7.15 AAT Bioquest
7.15.1 AAT Bioquest Company Summary
7.15.2 AAT Bioquest Business Overview
7.15.3 AAT Bioquest CD161 Antibody Major Product Offerings
7.15.4 AAT Bioquest CD161 Antibody Revenue in Global Market (2018-2023)
7.15.5 AAT Bioquest Key News & Latest Developments
7.16 Biobyt
7.16.1 Biobyt Company Summary
7.16.2 Biobyt Business Overview
7.16.3 Biobyt CD161 Antibody Major Product Offerings
7.16.4 Biobyt CD161 Antibody Revenue in Global Market (2018-2023)
7.16.5 Biobyt Key News & Latest Developments
7.17 Jingjie PTM BioLab
7.17.1 Jingjie PTM BioLab Company Summary
7.17.2 Jingjie PTM BioLab Business Overview
7.17.3 Jingjie PTM BioLab CD161 Antibody Major Product Offerings
7.17.4 Jingjie PTM BioLab CD161 Antibody Revenue in Global Market (2018-2023)
7.17.5 Jingjie PTM BioLab Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. CD161 Antibody Market Opportunities & Trends in Global Market
Table 2. CD161 Antibody Market Drivers in Global Market
Table 3. CD161 Antibody Market Restraints in Global Market
Table 4. Key Players of CD161 Antibody in Global Market
Table 5. Top CD161 Antibody Players in Global Market, Ranking by Revenue (2022)
Table 6. Global CD161 Antibody Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global CD161 Antibody Revenue Share by Companies, 2018-2023
Table 8. Global Companies CD161 Antibody Product Type
Table 9. List of Global Tier 1 CD161 Antibody Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 CD161 Antibody Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global CD161 Antibody Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - CD161 Antibody Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - CD161 Antibody Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global CD161 Antibody Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - CD161 Antibody Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - CD161 Antibody Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global CD161 Antibody Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global CD161 Antibody Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global CD161 Antibody Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America CD161 Antibody Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America CD161 Antibody Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe CD161 Antibody Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe CD161 Antibody Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia CD161 Antibody Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia CD161 Antibody Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America CD161 Antibody Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America CD161 Antibody Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa CD161 Antibody Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa CD161 Antibody Revenue, (US$, Mn), 2024-2029
Table 30. BD Biosciences Company Summary
Table 31. BD Biosciences CD161 Antibody Product Offerings
Table 32. BD Biosciences CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 33. BD Biosciences Key News & Latest Developments
Table 34. GeneTex Company Summary
Table 35. GeneTex CD161 Antibody Product Offerings
Table 36. GeneTex CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 37. GeneTex Key News & Latest Developments
Table 38. RayBiotech Company Summary
Table 39. RayBiotech CD161 Antibody Product Offerings
Table 40. RayBiotech CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 41. RayBiotech Key News & Latest Developments
Table 42. LifeSpan BioSciences Company Summary
Table 43. LifeSpan BioSciences CD161 Antibody Product Offerings
Table 44. LifeSpan BioSciences CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 45. LifeSpan BioSciences Key News & Latest Developments
Table 46. BioLegend Company Summary
Table 47. BioLegend CD161 Antibody Product Offerings
Table 48. BioLegend CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 49. BioLegend Key News & Latest Developments
Table 50. Abeomics Company Summary
Table 51. Abeomics CD161 Antibody Product Offerings
Table 52. Abeomics CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 53. Abeomics Key News & Latest Developments
Table 54. Bioss Company Summary
Table 55. Bioss CD161 Antibody Product Offerings
Table 56. Bioss CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 57. Bioss Key News & Latest Developments
Table 58. Novus Biologicals Company Summary
Table 59. Novus Biologicals CD161 Antibody Product Offerings
Table 60. Novus Biologicals CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 61. Novus Biologicals Key News & Latest Developments
Table 62. Tonbo Biosciences Company Summary
Table 63. Tonbo Biosciences CD161 Antibody Product Offerings
Table 64. Tonbo Biosciences CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 65. Tonbo Biosciences Key News & Latest Developments
Table 66. Bio-Rad Company Summary
Table 67. Bio-Rad CD161 Antibody Product Offerings
Table 68. Bio-Rad CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 69. Bio-Rad Key News & Latest Developments
Table 70. Cell Sciences Company Summary
Table 71. Cell Sciences CD161 Antibody Product Offerings
Table 72. Cell Sciences CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 73. Cell Sciences Key News & Latest Developments
Table 74. Miltenyi Biotec Company Summary
Table 75. Miltenyi Biotec CD161 Antibody Product Offerings
Table 76. Miltenyi Biotec CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 77. Miltenyi Biotec Key News & Latest Developments
Table 78. R&D Systems Company Summary
Table 79. R&D Systems CD161 Antibody Product Offerings
Table 80. R&D Systems CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 81. R&D Systems Key News & Latest Developments
Table 82. BMA Biomedicals Company Summary
Table 83. BMA Biomedicals CD161 Antibody Product Offerings
Table 84. BMA Biomedicals CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 85. BMA Biomedicals Key News & Latest Developments
Table 86. AAT Bioquest Company Summary
Table 87. AAT Bioquest CD161 Antibody Product Offerings
Table 88. AAT Bioquest CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 89. AAT Bioquest Key News & Latest Developments
Table 90. Biobyt Company Summary
Table 91. Biobyt CD161 Antibody Product Offerings
Table 92. Biobyt CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 93. Biobyt Key News & Latest Developments
Table 94. Jingjie PTM BioLab Company Summary
Table 95. Jingjie PTM BioLab CD161 Antibody Product Offerings
Table 96. Jingjie PTM BioLab CD161 Antibody Revenue (US$, Mn) & (2018-2023)
Table 97. Jingjie PTM BioLab Key News & Latest Developments
List of Figures
Figure 1. CD161 Antibody Segment by Type in 2022
Figure 2. CD161 Antibody Segment by Application in 2022
Figure 3. Global CD161 Antibody Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global CD161 Antibody Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global CD161 Antibody Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by CD161 Antibody Revenue in 2022
Figure 8. By Type - Global CD161 Antibody Revenue Market Share, 2018-2029
Figure 9. By Application - Global CD161 Antibody Revenue Market Share, 2018-2029
Figure 10. By Type - Global CD161 Antibody Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global CD161 Antibody Revenue Market Share, 2018-2029
Figure 12. By Application - Global CD161 Antibody Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global CD161 Antibody Revenue Market Share, 2018-2029
Figure 14. By Region - Global CD161 Antibody Revenue Market Share, 2018-2029
Figure 15. By Country - North America CD161 Antibody Revenue Market Share, 2018-2029
Figure 16. US CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 17. Canada CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe CD161 Antibody Revenue Market Share, 2018-2029
Figure 20. Germany CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 21. France CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 23. Italy CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 24. Russia CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia CD161 Antibody Revenue Market Share, 2018-2029
Figure 28. China CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 29. Japan CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 32. India CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America CD161 Antibody Revenue Market Share, 2018-2029
Figure 34. Brazil CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa CD161 Antibody Revenue Market Share, 2018-2029
Figure 37. Turkey CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 38. Israel CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 40. UAE CD161 Antibody Revenue, (US$, Mn), 2018-2029
Figure 41. BD Biosciences CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. GeneTex CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. RayBiotech CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. LifeSpan BioSciences CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. BioLegend CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Abeomics CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Bioss CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Novus Biologicals CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Tonbo Biosciences CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Bio-Rad CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Cell Sciences CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Miltenyi Biotec CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. R&D Systems CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. BMA Biomedicals CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. AAT Bioquest CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Biobyt CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Jingjie PTM BioLab CD161 Antibody Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 抗CD3抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
  • CEP55抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
  • ECHS1抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
  • IFIT3抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
  • INTS3抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC12288 )"CD161抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル" (英文：CD161 Antibody Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。